Takami Hirokazu, Graffeo Christopher S, Perry Avital, Giannini Caterina, Daniels David J
Departments of1Neurologic Surgery and.
2Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
J Neurosurg. 2020 Feb 7;134(2):437-445. doi: 10.3171/2019.10.JNS191136. Print 2021 Feb 1.
Intracranial germ cell tumors (iGCTs) often arise at the neurohypophysis, their second most common origination, following the pineal region. Neurohypophyseal iGCTs present with stereotypical symptoms, including pituitary dysfunction and visual field deficit, due to their suprasellar location. The goal of this study was to present a large, longitudinal single-institution experience with neurohypophyseal iGCTs to better understand their natural history and identify opportunities for further improvement in treatment outcomes.
This is a retrospective, single-institution cohort study of neurohypophyseal iGCTs treated between 1988 and 2017, with a focus on the epidemiology, presentation, natural history, and treatment.
Thirty-five neurosurgically managed patients met inclusion criteria; the median age was 18 years (3 months to 49 years), and 74% of patients were male (n = 26). Thirty-one tumors were germinomas, and 4 were nongerminomatous iGCTs. Presenting symptoms included pituitary insufficiency in 76% (n = 25), visual deficit in 45% (n = 15), and diabetes insipidus (DI) in 61% (n = 20) of patients. Index symptoms included isolated DI in 10 (36%), isolated hormone deficiency in 14 (50%), and concomitant DI and hormone deficiency symptoms in 4 (14%). Radiographic diagnostic latency was common, occurring at a median of 363 days (range 9-2626 days) after onset of the first symptoms and was significantly associated with both DI and hormone deficiency as the index symptoms (no DI vs DI: 360 vs 1083 days, p = 0.009; no hormone deficiency vs hormone deficiency: 245 vs 953 days, p = 0.004). Biochemical abnormalities were heterogeneous; each pituitary axis was dysfunctional in at least 1 patient, with most patients demonstrating at least 2 abnormalities, and pretreatment dysfunction demonstrating a nonsignificant trend toward association with long-term posttreatment hormone supplementation. Among germinomas, whole-brain or whole-ventricle radiotherapy demonstrated significantly improved progression-free and overall survival compared with local therapy (p = 0.009 and p = 0.004, respectively).
Neurohypophyseal iGCTs are insidious tumors that may pose a diagnostic dilemma, as evidenced by the prolonged latency before radiographic confirmation. Serial imaging and close endocrine follow-up are recommended in patients with a characteristic clinical syndrome and negative imaging, due to the propensity for radiographic latency. Pretreatment biochemical abnormalities may indicate higher risk of posttreatment pituitary insufficiency, and all patients should receive careful endocrine follow-up. Local radiotherapy is prone to treatment failure, while whole-ventricle treatment is associated with improved survival in germinomas.
颅内生殖细胞肿瘤(iGCTs)常起源于神经垂体,这是其第二常见的起源部位,仅次于松果体区。由于神经垂体iGCTs位于鞍上,常表现出典型症状,包括垂体功能障碍和视野缺损。本研究的目的是展示一个大型的、单中心的神经垂体iGCTs纵向研究经验,以更好地了解其自然病史,并确定进一步改善治疗结果的机会。
这是一项对1988年至2017年间接受治疗的神经垂体iGCTs进行的回顾性、单中心队列研究,重点关注流行病学、临床表现、自然病史和治疗情况。
35例接受神经外科治疗的患者符合纳入标准;中位年龄为18岁(3个月至49岁),74%的患者为男性(n = 26)。31例肿瘤为生殖细胞瘤,4例为非生殖细胞性iGCTs。出现的症状包括76%(n = 25)的患者有垂体功能不全,45%(n = 15)的患者有视力缺陷,61%(n = 20)的患者有尿崩症(DI)。首发症状包括单纯DI 10例(36%)、单纯激素缺乏14例(50%)以及DI和激素缺乏症状并存4例(14%)。影像学诊断延迟很常见,首次症状出现后中位延迟时间为363天(范围9 - 2626天),且与以DI和激素缺乏作为首发症状显著相关(无DI与有DI:360天对1083天,p = 0.009;无激素缺乏与有激素缺乏:245天对953天,p = 0.004)。生化异常具有异质性;每个垂体轴至少有1例患者功能失调,大多数患者表现出至少2种异常,且治疗前功能障碍与治疗后长期激素补充之间存在无显著意义的关联趋势。在生殖细胞瘤中,与局部治疗相比,全脑或全脑室放疗显示无进展生存期和总生存期显著改善(分别为p = 0.009和p = 0.004)。
神经垂体iGCTs是隐匿性肿瘤,可能造成诊断困境,影像学确诊前的延迟时间延长即证明了这一点。对于具有特征性临床综合征且影像学检查为阴性的患者,由于存在影像学延迟的倾向,建议进行系列影像学检查和密切的内分泌随访。治疗前的生化异常可能表明治疗后垂体功能不全的风险较高所有患者均应接受仔细的内分泌随访。局部放疗容易治疗失败,而全脑室治疗与生殖细胞瘤患者生存率提高相关。